Showing 2571-2580 of 3014 results for "".
- Novan, Inc. Launches IPO, Lists on NASDAQhttps://practicaldermatology.com/news/novan-inc-launches-ipo-lists-on-nasdaq/2458429/Novan, Inc. (the “Company” or “Novan”) today announced the pricing of the Company’s initial public offering of 4,100,000 shares of common stock at a price to the public of $11.00 per share. The common stock of Novan has been approved for listing on the NASDAQ Global
- Ditch the Itch: EpiCeram Helps Relieve Eczema Symptomshttps://practicaldermatology.com/news/ditch-the-itch-epiceram-helps-relieve-eczema-symptoms/2458431/A new survey from PuraCap Pharmaceutical sheds light on the emotional and physical effects of eczema, a pervasive condition that affects 31.6 million people in the US. According to the survey, a large number of people are not getting the relief they need
- FDA Bans 19 Ingredients from Hand Soapshttps://practicaldermatology.com/news/fda-no-more-antibacterials-allowed-in-consumer-soaps/2458446/Antibacterial soaps will soon be gone from store shelves, according to a new rule from the US Food and Drug Administration (FDA). This
- Mass Spectrometry Test Helps Distinguish Atypical Moles From Melanomahttps://practicaldermatology.com/news/mass-spectrometry-test-helps-distinguish-atypical-moles-from-melanoma/2458447/Mass spectrometry may aid in the diagnosis of atypical moles, new research suggests. In this study, mass spectrometry, which analyzes the level of proteins within mole cells, correlated better than the gold standard of histologic examination to determine if an atypical mole was benign or
- FDA Approves Enbrel Biosimilarhttps://practicaldermatology.com/news/fda-approves-enbrel-biosimilar/2458451/The U.S. Food and Drug Administration (FDA) approved Erelzi for multiple inflammatory diseases. Erelzi is a biosimilar to Enbrel (etanercept), which was originally licensed in 1998. The move is no surprise given the unanimous backing of an FDA advisory arm last month. There are now
- Cetaphil® Marks Fifth Year of Support for CSDF and Camp Wonderhttps://practicaldermatology.com/news/cetaphil-marks-fifth-year-of-support-for-csdf-and-camp-wonder/2458452/Galderma Laboratories, L.P., makers of Cetaphil, is celebrating the fifth consecutive year of its "Meaningphil™" partnership with the Children's Skin Disease Foundation (CSDF) and Camp Wonder.</
- Chris Payne Named Chief Marketing Officer at PCA Skinhttps://practicaldermatology.com/news/chris-payne-named-chief-marketing-officer-at-pca-skin/2458454/Chris Payne has been named Chief Marketing Officer at Scottsdale, AZ-based PCA Skin. In this role, Payne will be responsible for leading all marketing and communication initiatives to drive growth of PCA SKIN through both professional and consum
- Kybella for Men May Mean Buh-Bye Beardshttps://practicaldermatology.com/news/kybella-for-men-may-mean-buh-bye-beards/2458456/If Allergan’s double-chin melting injectable Kybella were to really take off among men, we may be seeing a lot fewer beards, jokes bearded Washington DC –based dermatologist Terrence Keaney, MD. Male aesthetics is a growing market,
- Study: Some Black Teens Pulled Between Health and Hairhttps://practicaldermatology.com/news/study-some-black-teens-pulled-between-health-and-hair/2458468/Some girls and women in the black community feel as if they have to choose between their health and their hair, and this may play a role in the high rates of obesity seen in this population, new research shows. Susan Woolford, M.D., MPH, , a pediatrician at the University
- Valeant Dermatology ASPIRE HIGHER Scholarship Program Names Winnershttps://practicaldermatology.com/news/valeant-dermatology-aspire-higher-scholarship-program-names-winners/2458472/Valeant Dermatology, a division of Valeant Pharmaceuticals North America LLC, announced the winners of its ASPIRE HIGHER Scholarship Program. Nine undergraduate and graduate students were selected from a pool of 970 applicants and awarded up to $10,000 each tow